Yet BPC-157, short for Body Protection Compound-157, has accumulated a striking body of preclinical evidence suggesting it accelerates tendon healing, repairs intestinal injury, modulates the nervous system, and does so without the toxicity profile that complicates many pharmacological interventions
DSIP's theoretical advantage (minimal next-day sedation and potential physiological sleep architecture improvement) has not been confirmed in modern trials
Common reports include soreness at the injection site, nausea, headache, and tiredness
For adverse events was same, the same article (Yaikwawong et al., 2024) was not included in the statistics, then the result changed from OR = 0.03, CI 95%: 0.03, 0.09 I 2 = 64% to OR = 0.01, 95% CI: 0.03, 0.06 I 2 = 23%